Pluri (PLUR) Stock Price & Analysis
PLUR Stock Chart & Stats
- Day’s Range
- ILA 391.00 - ILA 435.00
- 52-Week Range
- ILA 280.00 - ILA 1,548.00
- Previous Close
- ILA 396.00
- Volume
- 29.63K
- Average Volume (3M)
- 11.05K
- Market Cap
- ILS 49.17M
- Enterprise Value
- ILS 43.10M
- Total Cash (Recent Filing)
- ILS 7.80M
- Total Debt (Recent Filing)
- ILS 34.91M
- Price to Earnings (P/E)
- ―
- Beta
- 0.39
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Strong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.
Strategic Partnerships
Strategic partnerships expand Pluri's market reach and provide additional funding, supporting long-term growth and innovation in its product pipeline.
Leadership Incentives
Aligning executive incentives with performance goals can drive strategic decision-making and improve operational efficiency, benefiting long-term company performance.
Bears Say
Financial Instability
Financial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.
Negative Cash Flow
Negative cash flow indicates ongoing operational challenges, which may hinder Pluri's ability to sustain operations and invest in future growth without additional financing.
Profitability Challenges
Ongoing profitability challenges with negative margins suggest difficulty in achieving sustainable earnings, impacting long-term financial health and investor confidence.
Pluri News
PLUR FAQ
What was Pluri’s price range in the past 12 months?
What is Pluri’s market cap?
When is Pluri’s upcoming earnings report date?
How were Pluri’s earnings last quarter?
Is Pluri overvalued?
Does Pluri pay dividends?
What is Pluri’s EPS estimate?
How many shares outstanding does Pluri have?
What happened to Pluri’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pluri?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Pluri
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yaacov Yanay
- Employees
- 92
- Website
- www.pluri-biotech.com
- Address
- MATAM Advanced Technology Park, Haifa, HA, 3508409, IL
Pluri (PLUR) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 8 | 0 | 4 |










